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Abstract
Background: Aim of this work was to assess loco-regional disease control in head and neck
cancer (HNC) patients treated with postoperative intensity modulated radiation therapy (pIMRT).
For comparative purposes, risk features of our series have been analysed with respect to
histopathologic adverse factors. Results were compared with an own historic conventional
radiation (3DCRT) series, and with 3DCRT and pIMRT data from other centres.
Between January 2002 and August 2006, 71 patients were consecutively treated with pIMRT for a
squamous cell carcinoma (SCC) of the oropharynx (32), oral cavity (22), hypopharynx (7), larynx
(6), paranasal sinus (3), and an unknown primary, respectively. Mean and median follow up was 19
months (2–48), and 17.6 months. 83% were treated with IMRT-chemotherapy. Mean prescribed
dose was 66.3 Gy (60–70), delivered with doses per fraction of 2–2.3 Gy, respectively.
Results: 2-year local, nodal, and distant control rates were 95%, 91%, and 96%, disease free and
overall survival 90% and 83%, respectively. The corresponding survival rates for the subgroup of
patients with a follow up time >12 months (n = 43) were 98%, 95%, 98%, 93%, and 88%,
respectively. Distribution according to histopathologic risk features revealed 15% and 85% patients
with intermediate and high risk, respectively. All loco-regional events occurred in the high risk
subgroup.
Conclusion:  Surgery followed by postoperative IMRT in patients with substantial risk for
recurrence resulted in high loco-regional tumor control rates compared with large prospective
3DCRT trials.
Background
Despite high dose postoperative irradiation in patients
with locally advanced head and neck cancer (HNC) with
certain high risk factors, loco-regional recurrences occur in
approximately 30% of the cases [1,2]. Three randomized
studies showed an increase of loco-regional control and
overall survival when postoperative radiation and con-
comitant chemotherapy are combined [2-4] (Table 1).
Accelerating treatment by using concomitant boost did
not result in a clear improvement of loco-regional control
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[5] except perhaps in patients with a longer interval
between surgery and radiation. In our own experience in
postoperative radiation using concomitant boost, local
control was 83% in accelerated vs 68% with conventional
fractionation (S Maurer, dissertation, Radiation Oncol-
ogy, University Hospital of Zurich, 1996). Since approxi-
mately 5 years, intensity modulated radiation therapy
(IMRT) has been introduced in the clinic and used in
HNC. This has resulted in a high loco-regional control [6-
8] and better tolerance [6], compared to the "traditional
3DCRT".
We are presently assessing the results focussing on the
validity of anatomic target definitions and the dosage,
respectively.
IMRT data on postoperative cohorts are still scant [9-12]
(Table 2). Risk feature assessment has not been discussed
in the published data.
In order to compare our own data with published results,
outcome parameters and risk factors as established by Ang
et al [5], have been used.
Results
Patient and tumor characteristics are listed in Table 3.
Postoperative HNC patients treated in the same time
interval for histopathologic diagnosis other than squa-
mous cell carcinoma (n = 15) have been excluded from
this analysis.
Local, nodal, distant control, disease free and overall sur-
vival rates at 2 years were 95, 91, 96%, 90% and 83%,
respectively, for the entire cohort (Figure 1a). The corre-
sponding survival rates for the subgroup of patients with
a follow up time >12 months (n = 43) were 98%, 95%,
98%, 93%, and 88%, respectively (Figure 1b).
The small number of events did not allow further sub-
group analysis with respect to diagnosis, age or gender.
When last seen, 63 patients (89%) were alive with no evi-
dence of disease, one was alive with disease, 3 patients
had died of disease, and 4 of independent reasons not
related to the tumor.
Staging according to pathologic features established by
Ang et al [5] revealed 15% and 85% patients with interme-
Table 1: Comparison with historic conventional postoperative three-dimensional radiation therapy (p3DCRT) data
2-year control rates
Author reference) n risk level % LRC % DFS % OAS % high risk pRT technique pRT dose cc ChTh
Aug et al [5] 151 HR ~72 na ~60 100% 3dcrt 63 Gy no
62 LR, IR ~95 na ~90 0% 3dcrt LR: no RT, IR: 57.6 Gy no
Cooper et al [4] 228 HR ~83 ~55 ~65 100% 3dcrt 60–66 Gy in 30–33 f yes
231 HR ~72 ~50 ~55 100% 3dcrt 60–66 Gy in 30–33 f no
Bernier et al [3] 167 HR ~82 ~67 ~75 > 60% 3dcrt 66 Gy in 33 f yes
167 HR ~70 ~48 ~61 > 60% 3dcrt 66 Gy in 33 f no
Bachaud et al [2] 39 HR 79 65 75 100% 3dcrt NA yes
44 HR 59 41 44 100% 3dcrt NA no
Porceddu et al [13] 47 HR ~73 ~56 ~62 100% 3dcrt mean 60 Gy (50–66) yes
own 60 HR 92 90 81 100% IMRT 60–70 Gy in 27–35 f most (>80%)
11 IR 100 90 90 0% IMRT 60–70 Gy in 27–35 f most (>80%)
Comparison with historic conventional postoperative three-dimensional radiation therapy (p3DCRT) data
Table 2: 
Author, ref (year) n pIMRT
(dIMRT)
HNC subsites T3/4, rec, OCC pIMRT dose Chemotherapy 2-y L(R)C median FU
Lee et al [15] (2003) 43 (107) all 53, 0, 2% 66 Gy 35% of pIMRT 83% LC 25 (6–78)
Chao et al [9] (2004) 74 (52) all 52, 0, 12% ~68 Gy (+/-4.7) none of pIMRT 90% LRC 26 (12–55)
Feng et al [10] (2005) 86 (72) all but NPC/SNC 90 lll/lV, 3, 23% ~70 Gy (66–76) 12% of all ~85% LRC 36 (6–127)
Yao et al [12] (2005) 51 (100) all 53, 0, 19% 64–66 Gy none of pIMRT ~92% LC 18 (2–60)
own (2006) 71 (230) all SCC 25, 18, 31% ~66 Gy (60–70) 83% of pIMRT 95% LC 17.6 (2–48)
91% NC
Published postoperative IMRT (pIMRT) results in head and neck cancer (HNC)
(dIMRT: number of patients treated with definitive IMRT, rec: recurrence, OCC: oral cavity cancer, FU: follow up)Radiation Oncology 2006, 1:40 http://www.ro-journal.com/content/1/1/40
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diate and high risk disease, respectively. Table 4 shows the
histopathologic risk factors, on which the risk stratifica-
tion is based.
Six patients with 3 local, 5 nodal, and 2 distant relapses
were observed. The follow up time is still short. However,
considering the fact that 90% of all loco-regional recur-
rences occurred during the first 12 months after comple-
tion of radiation in our definitive IMRT cohort (64 out of
69 local and nodal events in 230 patients), and all events
observed in the pIMRT cohort occurred during the first 10
months, the observation interval of median/mean 17.6/
19 months (2–48) is expected to be long enough for a rep-
resentative estimation of the 2-year outcome in pIMRT.
All patients with loco-regional failure belong to the his-
topathologic high risk group. Two of the three failed
patients were referred for resected recurrence of an oral
cavity and glottic cancer, respectively. The third locally
failed patient suffered from a pT2pN2 oral cavity tumor.
Nodal failure in locally controlled patients occurred in
three patients. None of the loco-regionally controlled
patients developed metastatic disease.
All nodal failures occurred in nodally dissected patients
with proven pN+ disease (ECE in 3/5).
The CT of all patients with loco-regional failures were
reviewed, and recurred tumor manifestations correlated
with the drawn contours and isodoses on the treatment
plan. Loco-regional failures were confirmed as 'in-field'
relapses (>95% of the tumor volume inside the 95% PTV
isodose) in all but one case with a superficial nodal
relapse (Figure 2a, b).
Treatment times
The interval between surgery and the start of radiation was
4–6 weeks (median 36 days) in 11, and >6 weeks (median
45 days) in 60 treated individuals; the pIMRT duration
was mean 44 days (37–47, Table 5). Using an slightly
accelerated dose per fraction to the SIB target volume (i.e.
2.11, 2.2, 2.3 Gy per fraction), as performed in 24 of the
71 SIB-IMRT cases, an additional mild dose acceleration
has been reached.
Toxicity
Acute toxicity was mild to moderate. No grade 4 reactions,
and no treatment interruptions occurred due to radiation
or chemotherapeutic side effects, respectively. A gastric
feeding tube was used in 10 patients (14%), body weight
in the entire cohort was mean 71 kg prior to radiation,
mean 68 kg at the end of pIMRT, and mean 67 kg at 1 year
from completion of radiation, respectively. The maximum
individual weight loss during radiation was 9% of the pre-
treatment weight.
No grade 4 reaction, and only one grade 3 late effect
(xerostomia) was observed in the 43 patients with an at
least 12 months follow up period.
Table 3: 
factors n
gender 61 m : 10 f
age 59 (38–85)
diagnosis
oropharynx 32
oral cavity 22
hypopharynx 7
sinus 3
larynx 6
unknown, N+ 1
T stages
Tx 1
T1 18
T2 21
T3 6
T4 12
recurrence * 13
N stages
N0 15
N1 4
N2a-b 43
N2c 6
N3 3
concomitant CT ** 59 (83%)
median/mean FU 17.6/19 months
Patient and tumor characteristics in 71 patients treated with 
postoperative SIB-IMRT
*: recurrence following surgery alone (none of all patients underwent 
previous irradiation; all recurred lesions have been re-operated prior 
to postoperative IMRT)
**: Cisplatinum based chemotherapy (in additional two patients with 
contraindications for cisplatinum, cetuximab has been given in 
combination with IMRT)
Table 4: 
Adverse factors n patients [na]
ECE nodal 33 [1]
>1 nodal group 30 [2]
>/= 2 pos LN 34 [2]
> 3 cm LN 19 [4]
OCC 22 [0]
R1 51 [5]
PNI 11 [6]
Histopathologic risk factors (na: not assessable, ECE: extra-capsular 
extension, LN: lymph node, OCC: oral cavity cancer, R1: 
microscopically positive margin, PNI: perineural infiltration)Radiation Oncology 2006, 1:40 http://www.ro-journal.com/content/1/1/40
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Discussion
Treatment outcome of HNC patients treated with postop-
erative IMRT has been assessed.
We found a high local-regional disease control rate in a
collective of 71 patients of these 60 had high risk features,
and 13 were referred for recurrent disease after surgery
alone.
Peters et al [1] (1993) and Ang et al [5] (2001) undertook
prospective randomized trials to address the validity and
dose of postoperative radiation, the impact of accelerating
postoperative radiation, and the importance of the overall
treatment time on outcome in 302 and 213 patients,
respectively. The authors found significantly higher loco-
regional control (LRC) and survival rates in non irradiated
low risk and irradiated intermediate risk patients com-
pared to high risk patients irradiated with higher doses. In
addition, for high risk patients, a trend toward higher LRC
was found when radiation was delivered in 5 rather than
in 7 weeks, and a significant LRC benefit was shown when
the interval between surgery and radiation in the 7-week
schedule was short. Consequently, the cumulative dura-
tion of combined therapy has a significant impact on LRC
and survival.
Concomitant chemotherapy with cisplatin has been
investigated in 3 randomised series:
a: 2-year actuarial local (LC, 95%), nodal (NC, 91%), distant control (DC, 96%), and disease free (DFS, 90%) and overall sur- vival rate (OAS, 83%) in 71 postoperative IMRT patients Figure 1
a: 2-year actuarial local (LC, 95%), nodal (NC, 91%), distant control (DC, 96%), and disease free (DFS, 90%) and overall sur-
vival rate (OAS, 83%) in 71 postoperative IMRT patients.b: 2-year actuarial local (LC, 98%), nodal (NC, 95%), distant control 
(DC, 98%), and disease free (DFS, 93%) and overall survival rate (OAS, 88%) in 43/71 postoperative IMRT patients with a fol-
low up period of >12 months.
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Figure 1a       Figure  1b
Table 5: 
postoperative SIB-IMRT schedules
n patients PTV1 PTV2 PTD PTV1/PTV2 (Gy) fractionation TRT (days)
47 30–35 × 2.0 Gy 30–35 × 1.64–1.8 Gy 60–70/48–56 5/w 38–47
16 30–33 × 2.11 Gy 30–33 × 1.64 Gy 63.3–69.6/49.2–54 5/w 40–45
7 27–30 × 2.2 27–30 × 1.8 Gy 59.4–66/48.6–54 5/w 37–40
1 27 × 2.3 (LN), 2.2 Gy 27 × 1.8 Gy 62.1, 59.4/48.6 5/w 37
Used simultaneously integrated boost (SIB) IMRT schedules in our postoperatively irradiated patients
(PTV1: planning target volume 1 = boost volume, PTV2: planning target volume 2 = elective treatment volume, PTD: prescribed total dose, TRT: 
total radiation time, 3DCRT: three-dimensional conformal radiation therapy)Radiation Oncology 2006, 1:40 http://www.ro-journal.com/content/1/1/40
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Bachaud et al [2] (1991) showed a significant improve-
ment of LRC as well as survival rates in a relatively small
number of patients (n = 83). These results have been con-
firmed and extended by Cooper et al [4], and Bernier et al
[3], respectively. Cooper et al [4] (Table 1) assessed 459
high risk patients enrolled into an intergroup phase lll
trial (RTOG, ECOG, SWOG) to test the hypothesis that
concurrent postoperative radiation-chemotherapy would
improve LRC compared to the radiation alone arm. The
difference was significant in favour to the combined
approach, with 82 vs 72%, respectively, at two years.
Similarly, in a prospective multicenter randomized study
with 334 stage lll and lV patients, in which our institution
participated, Bernier et al [3] (Table 1) compared postop-
erative combined radiation-chemotherapy with postoper-
ative radiation alone. The authors found a significantly
increased 5-year progression-free survival and overall sur-
vival rates in favour to the combined arm, with 47 vs 36%,
and 53 vs 40%, respectively.
Comparison with postoperative conventional radiation 
(p3DCRT) data
Table 1 shows outcome data of the above mentioned
three large prospective p3DCRT trials [3-5] and two
smaller prospective single institution series [2,13],
addressing the outcome following p3DCRT combined
with chemotherapy. In high risk cohorts treated with
p3DCRT without chemotherapy [3-5], highly concordant
LRC rates of 70 and 72% were reported, with an increase
of approximately 10% up to ~82%, when chemotherapy
was added [3,4]. Our high risk pIMRT-chemotherapy
cohort resulted in higher control rates regarding LRC, dis-
ease free survival and overall survival, respectively.
We stratified our patients according to the risk factors
established and used by Ang et al [5] (see section 'meth-
ods', and Table 4). Cooper et al [4] defined 'high risk' as
any or all of the following: invasion of >/= 2 lymph nodes,
ECE, R1. Bernier et al [3] used ECE, R1, PNI, and vascular
tumor embolism for definition of high risk situations,
Superficial nodal recurrence (ipsilateral dorsolateral node) in a patient with a pT2 pN2b supraglottic larynx carcinoma Figure 2
Superficial nodal recurrence (ipsilateral dorsolateral node) in a patient with a pT2 pN2b supraglottic larynx carcinoma. Preop-
erative diagnostic images did not show any suspicious superficial nodes, nor were any enlarged nodes visible in the postopera-
tive planning computed tomography a: IMRT treatment plan, PTV1 (black line): 'build up' effect in the skin/subcutaneous region 
of interest (ROI, white dotted line) which was not intended to be included into the PTV1. b: posttreatment follow up com-
puted tomography scan revealed a superficial lymph node metastasis (ROI), located in the former 'build up' area
Figure 2a Figure 2bRadiation Oncology 2006, 1:40 http://www.ro-journal.com/content/1/1/40
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while Porceddu et al [13] considered the presence of ECE,
positive or close margins (<5 mm), and loco-regional
recurrence as high risk features. Bachauds' et als' [2]
patient inclusion criterion was ECE.
Treatment associated factors impacting on loco-regional 
control in pIMRT
a) Total treatment time (TTT)
Postoperative IMRT was performed using dose painting
with SIB. SIB schedules with a slightly increased dose per
fraction translate into a mild treatment acceleration.
Treatment acceleration has been shown to improve out-
come in historic 3DCRT series. The SIB schedules used in
pIMRT are listed in Table 5. Mild treatment acceleration
was therefore performed in 24 patients irradiated with
doses per fraction higher than 2.0 Gy (2.11, 2.2 or 2.3 Gy/
d) to the boost volume.
On the other hand, our collective showed unfavourable
features regarding the treatment timing, with a surgery to
start of radiation interval of > 6 weeks, and the TTT (time
from surgery to the last radiation therapy day) of >12
weeks in the majority of patients. The TTT in the four
patients who locally recurred was 12, 14, 18, and 22
weeks, respectively. Reasons for this unfavourably long
TTT are multifactorial (such as time gap between surgery
and referral for first presentation, dental care prior to
planning computer tomography, IMRT planning time,
and others more).
Both the interval between surgery and the start of radia-
tion of > 6 weeks, and the TTT of >13 weeks, have been
shown to translate into a highly significantly lower loco-
regional control rate by Ang et al [5]. Consecutively, short-
ening of TTT may be a possibility to further optimize out-
come.
b) concomitant radiation-chemotherapy
The advantage of the combined radio-chemotherapeutic
approach in the postoperative situation has clearly been
shown. The statistically significant increase of LRC is
approximately 10% [2-4,13] (Table 1).
c) IMRT
IMRT technique offers a clear benefit in terms of increased
treatment tolerance (xerostomia [14], mandible bone
necrosis [8]), and may result in an increase of LRC in dif-
ficult anatomic situations (e.g. posterior pharyngeal wall
[7], upper level 2, skull base) by permitting somewhat
higher doses to the tumor. IMRT seems to be an addi-
tional beneficial factor in improving outcome in postop-
erative HNC. Better outcome compared to historic 3DCRT
cohorts has been reported for definitive IMRT (dIMRT) in
pharyngeal tumors [15,7,16].
There are presently only few reports on pIMRT (Table 2).
In conclusion, pIMRT in HNC, as reported by other cen-
tres [9-12,16], has resulted in local control or LRC rates
ranging between 81 and 95%, respectively, which is in
concordance with our results. A direct comparison
between the cited pIMRT series is, however, limited
because the risk factors have not been indicated.
In a historic small p3DCRT series from our institution (S
Maurer, dissertation, Radiation Oncology, University
Hospital of Zurich, 1996) from the time interval when
conventional fractionation (5× 1.8 Gy per week) was
replaced by an accelerated boost schedule (see section
'patients' in the method's section), the first 18 accelerated
patients showed an actuarial 2-year local control of ~82%
vs 68% in 41 conventionally treated patients, with a min-
imal/maximal follow up time of 16/63 months each
group. The absolute recurrence rate was 22 vs 49%, respec-
tively. No concomitant chemotherapy was given at that
time.
We found no published reports comparing intra-institu-
tional historic p3DCRT to pIMRT results.
Conclusion
Surgery followed by postoperative IMRT in patients with
high risk for recurrence resulted in high loco-regional
tumor control rates compared with large prospective
3DCRT trials.
Methods
Patients
Between January 2002 and August 2006, 71 of 320 HNC
IMRT patients were treated with postoperative IMRT
(pIMRT). During the first year, when IMRT was clinically
implemented at our institution, for capacity reasons only
few postoperative patients could be included into the
IMRT program. Since the beginning of 2003, all HNC
patients referred for curative (definitive or postoperative)
radiation therapy have been treated with IMRT. No
patient selection was performed. Patient and tumor char-
acteristics are presented in Table 3.
In 9 of 15 patients without clinical or radiological signs of
nodal involvement, no neck dissection has been per-
formed.
Therapeutic decisions for these patients were made at
weekly interdisciplinary HNC tumor boards. All patients
were operated at the joint Head and Neck Surgery, or
Head, Neck and Maxillofacial Surgery, both at the Univer-
sity Hospital of Zurich. Similarly, histopathologic exami-
nations and diagnosis have been performed by head and
neck tumor specialists at the Institution of Pathology at
the University Hospital of Zurich.Radiation Oncology 2006, 1:40 http://www.ro-journal.com/content/1/1/40
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During the course of irradiation, all patients were clini-
cally assessed at regular weekly intervals, at 2 weeks and at
2 months after completion of treatment.
Approximately 6 weeks after completion of treatment all
patients were also seen regularly in our joint clinics at the
Department of Head and Neck Surgery or Head, Neck and
Maxillofacial Surgery. Further follow up visits were sched-
uled every 2 – 3 months in the first 2 years, 3 – 4 monthly
in the third year. When clinical and/or endoscopic exam-
ination showed no evidence of disease annual radiologi-
cal investigations were performed. Suspect findings were
specified with computed tomography (CT), magnetic res-
onance imaging (MIR), and/or positron emission tomog-
raphy/CT (PET/CT), suspect lymph nodes by needle
aspiration and/or biopsy, respectively.
Since 1991, we used a risk stratification following the
scheme described by Peters et al [1], when the authors
showed the prognostic significance of the risk factors as
listed in Table 4. In patients with low risk of recurrence,
usually no postoperative radiation was performed.
Because the data of Peters et al showed a loco-regional
recurrence rate of approximately 30% after 63–68.4 Gy
(oral presentation at ESTRO 1990, Monte Catini), we
changed the postoperative fractionation to a concomitant
boost regime, otherwise we used a dosage comparable to
the dose as used by Peters et al. This institutional dose
concept for postoperative situations was basically taken
over when IMRT as a novel technology was implemented
(see section 'radiation' below).
Actuarial disease outcome was calculated using Kaplan
Meier survival curves.
Results were compared with data from 3DCRT series and
IMRT cohorts reported from other centres.
Risk levels are defined as follows, based on the pathologic
risk factors listed in Table 4:
• low risk: no adverse pathologic factor
• intermediate risk: only one adverse factor other than
extra-capsular extension
(ECE)
• high risk: ECE, or >/= 2 adverse factors
In addition, we considered recurrences as intermediate
risk, and as high risk, when in combination with one of
the adverse factors listed above.
Radiation treatment
Schedules
Total doses and doses per fraction of the SIB-IMRT sched-
ules used are listed in Table 5.
High risk patients were treated with mean 67 Gy (60–70),
intermediate risk patients with mean 64 Gy (60–68),
respectively. Prescribed doses were calculated as the mean
of the nominal dose to the high dose planning target vol-
ume (PTV1).
One patient has been treated with 2.3 Gy per session to
62.1 Gy for bulky nodal disease.
Planning target volumes (PTVs)
All patients were treated using simultaneously integrated
boost technique [6].
-high dose planning target volume (PTV1):
High risk regions (the area of operated large tumors, areas
of operated tumors with positive resection margin (R1),
operated lymph node metastases measuring >3 cm, nodes
with ECE, multiple positive nodes) were included in the
PTV1. The operated primary and nodal gross tumor vol-
ume (pGTV) has been defined by contouring the ana-
tomic region of the initial primary and nodal GTV,
considering the preoperative diagnostics and the clinical
and histological findings. The PTV1 includes the pGTV
with a safety margin of between 1.0 and 1.5 cm, and was
extended also 1.0 to 1.5 cm above and below. All patients
underwent a pre-therapeutic fused positron-emission
tomography and computed tomography (PET-CT), facili-
tating the identification of initial gross tumor volumes.
-elective planning target volume (PTV2): for defining the
elective lymph node regions, the RTOG standard atlas
(RTOG homepage: http://www.rtog.org) has been used.
Regions with intermediate risk were treated with doses of
56–60 Gy, elective lymphatic pathways have been treated
with 46–54 Gy, respectively.
Bilateral nodal irradiation has been performed in all
tumors extending to the midline (except of nodally nega-
tive sinonasal cancer), in all large pT2 and any size >pT2
staged primaries. In cases of unilateral involvement or
cN0, the upper part of level II was not included.
Chemotherapy
All high risk patients with no specific contraindications
were simultaneously treated with cisplatin based chemo-
therapy (n = 59, 83% of all pIMRT patients). One cisplatin
application consisted of 40 mg/m2/radiation week. 5Publish with BioMed Central    and   every 
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patients had 1–3 applications, 54 patients tolerated 4–7
applications, respectively.
12 patients had no cisplatin chemotherapy; two of them
underwent combined cetuximab therapy.
The high percentage of combined treated individuals is
related to the fact that IMRT was implemented in our
institution towards the end of 2001, when first data on the
benefit of combining radiation with chemotherapy were
available [3], confirming earlier results of Bachaud et al
[2]. In consequence, the combined modality approach in
a postoperative setting was adopted as our institutional
standard.
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